Correction to: Jake et al., Formulation and delivery strategies of ibuprofen: challenges and opportunities

This article refers to:

Formulation and delivery strategies of ibuprofen: challenges and opportunities

Jake I, Afrina A, Nazrul I. Formulation and delivery strategies of ibuprofen: challenges and opportunities. Drug Dev Ind Pharm. 2017;44:173–183. http://doi.org/10.1080/03639045.2017.1391838

When the above article was first published online, Table 1 contained significant number of errors.

Table 1. Pharmacokinetics (C_max and t_max) of available ibuprofen oral products.

Dosage forms and delivery	Cmax (μg/mL)	tmax (h)	Reference
Doloraz^® suspension (100 mg)	10.05 ± 1.9	0.9 ± 0.58	[109]
Brufen^® suspension (100 mg)	9.92 ± 2.1	0.80 ± 0.42	[109]
Algidrin^® Pediátrico suspension (400 mg)	S: 22.39 ± 5.3 R: 21.74 ± 4	S: 0.5 R: 0.5	[110]
Dalsy^® suspension (400 mg)	S: 19.97 ± 3.2 R: 15.2 ± 2	S: 1.3 R: 1.0	[110]
Saridon^® N ibuprofen sodium dihydrate tablets (400 mg)	47.6 ± 8.7	0.6 ± 0.3	[111]
Nurofen^® tablets (400 mg)	36.1 ± 7.3 36.8 ± 9.4	2.0 1.4 ± 1.1	[18,111]
Advil^® tablets (400 mg)	37.7 ± 8.4	1.4	[18]
Advil^® film-coated tablets (400 mg)	50.6 ± 10.3	0.51	[18]
Motrin^® IB tablets (400 mg)	37.4 ± 7.8	2.0	[18]
Nurofen Express^® caplets containing ibuprofen lysinate (400 mg)	49.9 ± 12.6	0.58	[18]
Dolormin^® film-coated ibuprofen lysinate tablets (400 mg)	43.4 ± 6.1	0.73 ± 0.3	[111]
15 min slow infusion (3 mg/mL, 100 mL)	40.3 ± 7.5	0	[111]
Advil^® Liqui-Gels^® liquid capsules (400 mg)	48.6 ± 11.2	0.68	[18]
Advil^® FastGel^® liquid capsules (400 mg)	46.8 ± 12.0	0.67	[18]
Dolgit^® Mikrogel topical gel (200 mg)	0.06 ± 0.02	1.5	[60]

R: R-ibuprofen; S: S-ibuprofen.

The correct table should be:

The authors apologize for this error.